IP Library Granted Patent US 10,111,861
Granted Patent B2
US 10,111,861 · App. 15/373,914 · Granted Oct 30, 2018

Treatment of breast cancer

Inventors: Andrew A. Protter (San Francisco, CA); Jennifer Richer (Aurora, CO); Dawn Cochrane (Aurora, CO)
Assignees: Medivation Prostate Therapeutics, Inc.; The Regents of the University of Colorado, a Body Corporate
A61K31/4184A61K31/4166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,861
App. No.
15/373,914
Granted
Oct 30, 2018
Kind
B2
Abstract

This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.

Claims (13)

1. A method of treating breast cancer, wherein cells of the breast cancer express detectable estrogen receptor but the breast cancer is resistant to endocrine therapy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of

2. The method of claim 1 , wherein the compound is enzalutamide:

3. The method of claim 1 , wherein the patient is post-menopausal.

4. The method of claim 1 , wherein the endocrine therapy is administration of an aromatase inhibitor.

5. The method of claim 1 , wherein the endocrine therapy is administration of an estrogen receptor modulator.

6. The method of claim 1 , wherein the breast cancer comprises cells that do not express detectable androgen receptor.

7. The method of claim 1 , wherein the breast cancer comprises cells that express an androgen receptor.

8. The method of claim 1 , further comprising administering to the patient a second therapeutic treatment.

9. The method of claim 2 , wherein the endocrine therapy is administration of an aromatase inhibitor.

10. The method of claim 2 , wherein the endocrine therapy is administration of an estrogen receptor modulator.

11. The method of claim 2 , wherein the breast cancer comprises cells that do not express detectable androgen receptor.

12. The method of claim 2 , wherein the breast cancer comprises cells that express an androgen receptor.

13. The method of claim 2 , further comprising administering to the patient a second therapeutic treatment.

Assignments (7)
CORRECTION OF EXECUTION DATE IN COVERSHEET Recorded Jun 28, 2023
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 064148/0840 →
CHANGE OF ADDRESS Recorded Apr 19, 2023
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 063377/0500 →
CHANGE OF ADDRESS Recorded May 5, 2021
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 056152/0220 →
CHANGE OF ADDRESS Recorded May 5, 2021
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 056152/0216 →
CHANGE OF NAME Recorded Oct 12, 2017
From: MEDIVATION PROSTATE THERAPEUTICS, INC.
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 044224/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: PROTTER, ANDREW A.
To: MEDIVATION PROSTATE THERAPEUTICS, INC.
Reel/Frame 040700/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: RICHER, JENNIFER; COCHRANE, DAWN
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 040700/0029 →
Continuity (3)
Continuation 14236036
Provisional Application 61513361 · Jul 29, 2011
Related Publication 20170087132A1 · Mar 30, 2017